Transcutaneous Auricular Vagus Nerve Stimulation for Pediatric Epilepsy
Not Applicable
- Conditions
- Epilepsy
- Registration Number
- NCT02004340
- Lead Sponsor
- China Academy of Chinese Medical Sciences
- Brief Summary
The purpose of this study is to determine whether transcutaneous auricular vagus nerve stimulation as a complementary therapy is effective in the treatment of pediatric epilepsy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
- Diagnosed as epilepsy;
- With age between 2-18 years old;
- The number and dose of the medication was kept constant no less than eight weeks before intervention;
- The patients or their guardians can count the frequency of the seizures and finish the study.
Exclusion Criteria
- The patient is receiving the VNS therapy;
- Accompanied with progressive central nervous system diseases;
- Have severe heart, liver ,kidney or blood diseases;
- Be pregnant or having the schedule of pregnancy in the study period.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method frequency of epileptic seizures Change from baseline at 8, 16, 24 weeks respectively in frequency of epileptic seizures
- Secondary Outcome Measures
Name Time Method Number of participants with adverse events as a measure of safety and tolerability participants will be followed for the duration of TVNS intervention, an expected average of 8 weeks"
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the antiepileptic effects of transcutaneous auricular vagus nerve stimulation in pediatric patients?
How does transcutaneous auricular vagus nerve stimulation compare to traditional vagus nerve stimulation in managing drug-resistant pediatric epilepsy?
Are there specific biomarkers that can predict response to transcutaneous auricular vagus nerve stimulation in children with epilepsy?
What are the potential adverse events associated with transcutaneous auricular vagus nerve stimulation in pediatric epilepsy patients and how are they managed?
What combination therapies have been explored with transcutaneous vagus nerve stimulation for pediatric epilepsy and how do they compare to monotherapy?
Trial Locations
- Locations (1)
Wei He
🇨🇳Beijing, China
Wei He🇨🇳Beijing, ChinaWei He, Dr.Contact86 10 64089403hazel7811@hotmail.com